{
  "id": 17068506,
  "title": "Should You Buy Royalty Pharma Stock Before Nov. 4?",
  "url": "https://urgent.news/2026/10/29/should-you-buy-royalty-pharma-stock-before-nov-4",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-29T13:30:00.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/10/29/should-you-buy-royalty-pharma-stock-before-nov-4/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "On November 4, Royalty Pharma (RPRX) will release its Q3 2026 earnings report. After a September setback due to a major drug candidate issue, the stock has been on an upward trajectory, nearing its 52-week high. While this may make some consider speculating on a post-earnings rally, it's important to maintain a long-term perspective with this stock. Although earnings day might not directly drive share price action, there are still reasons to remain bullish on Royalty Pharma's long-term potential. Analysts predict an 8.7% sales growth and essentially zero earnings growth for the quarter ending September 30. However, these forecasts have been gradually revised upwards since August, when Royalty Pharma reported solid results, including a 14% increase in royalty receipts. Given its business model, investors see the company as prone to \"lumpy\" results. Analysts anticipate steady royalty revenue but fewer one-time milestone payments. Positive news on key drug candidates, such as cancer treatments from Johnson & Johnson and Revolution Medicines, as well as other Royalty Pharma drug candidates, may lead to a positive market reaction. Conversely, negative pipeline news or an earnings release that under-delivers could trigger a bearish response. If Royalty Pharma can maintain double-digit returns from its drug development funding and smooth out its earnings, trading at approximately 12 times forward adjusted earnings, the stock could potentially reach a mid-to-high teens forward multiple, comparable to more established biotech stocks.",
  "summary": "Don't expect earnings day to sustain the stock's recent rally.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}